Paper
Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial
International Journal of Gynecological Cancer · 2026 · Scott E Jordan, Antonio González-Martin, Robert Morlock et al.
